Evidence Level
Moderate
Vinpocetine has been used clinically in Europe and Japan since the 1970s, primarily for cerebrovascular disorders. A 2003 Cochrane review (Szatmári & Whitehouse) found evidence of cognitive benefit but noted that most trials were small and methodologically limited. Larger, well-designed trials are still needed. The compound's selectivity for cerebral blood vessels is well-established pharmacologically. Its regulatory status remains debated in the US, where the FDA has questioned whether it qualifies as a dietary supplement ingredient.